The Recall Desk

Hazard

Allergic Reaction recalls

206 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
206
Critical
5
Severe
179
Most recent
2025-12-03

Of the 206 allergic reaction recalls we have scored against our rubric, 5 (2%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 179 (87%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergic reaction recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

151–175 of 206

  • SevereFDA (Drugs)·D-903-2015·2015-04-29

    Attix Pharmaceuticals Recalls Spectinomycin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Spectinomycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Spectinomycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-838-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pheniramine Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pheniramine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pheniramine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-849-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Acetate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to a risk of penicillin cross-contamination.

    Product
    Potassium Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-934-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tolfenamic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tolfenamic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tolfenamic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-747-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lamotrigine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling lamotrigine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lamotrigine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-549-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromocriptine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bromocriptine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Bromocriptine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-785-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methotrexate Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methotrexate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methotrexate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-689-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flutamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flutamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-777-2015·2015-04-29

    Attix Pharmaceuticals Recalls Melphalan API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Melphalan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Melphalan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-516-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amitriptyline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amitriptyline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amitriptyline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-792-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methylprednisolone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methylprednisolone Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methylprednisolone Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-597-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clopidogrel Bisulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clopidogrel Bisulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Clopidogrel Bisulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-544-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bisacodyl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bisacodyl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bisacodyl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-870-2015·2015-04-29

    Attix Pharmaceuticals Recalls Proparacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Proparacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Proparacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-941-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trehalose Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trehalose Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trehalose Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-565-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carvedilol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carvedilol active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Carvedilol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-667-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etravirine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etravirine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Etravirine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-517-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Amlodipine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-572-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cephalexin Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-793-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metronidazole Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metronidazole Base active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metronidazole Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-931-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tizanidine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tizanidine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tizanidine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-864-2015·2015-04-29

    Attix Pharmaceuticals Recalls Procaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Procaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Procaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-573-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cetirizine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Cetirizine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-623-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexamethasone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dexamethasone Base active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dexamethasone Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide